By Daniel Sabet · Cannabis CFO & Financial Advisor, GreenGrowth CPAs · 280E, Tax Strategy & Growth Planning · Los Angeles, CA | Published August 2026 | Cannabis Advisory
Cannabis business valuation looks like ordinary business valuation until you open the financials. Then the standard approach falls apart. Reported earnings are artificially suppressed by Section 280E, market comparables barely exist, and a licence may carry more value than the operation attached to it. Anyone applying a straight EBITDA multiple to a licensed operator is valuing a distortion, and the April 2026 rescheduling order made that gap wider rather than narrower.
QUICK ANSWER
Cannabis business valuation estimates what a licensed operator is worth for a sale, an investment, a partner exit, or a tax or litigation purpose. It differs from ordinary valuation in four ways. Section 280E suppresses reported earnings, so the numbers need normalising before any multiple applies. Reliable market comparables are scarce, because private transactions are undisclosed and public multiples reflect capital access rather than operations. Licence value depends heavily on whether the state limits licences. And the buyer inherits the seller’s open tax positions, which diligence prices in.
Cannabis Business Valuation: At a Glance
What Makes It Different From Ordinary Valuation
- 280E distorts the starting point: Reported net income understates the real economics, so normalising earnings comes before any multiple.
- Rescheduling re-rated the market: Medical activity left 280E in April 2026, so trailing financials describe a tax position that no longer exists.
- The licence is a separate asset: In a limited-licence state it can carry most of the value. In an unlimited state it carries very little.
- Comparables barely work: Private deals go undisclosed and public multiples reflect capital access and uplisting expectations rather than operations.
- Tax exposure transfers: An aggressive prior-year COGS allocation or an amended 280E refund claim becomes the buyer’s problem after closing.
- Records decide credibility: If seed-to-sale, point of sale and the ledger disagree, a buyer discounts everything rather than untangling it.
- GreenGrowth’s role: We normalise the earnings and build the file the number rests on. Book a valuation readiness review →
Why Standard Multiples Fail in Cannabis Business Valuation
Most businesses value on a multiple of earnings. Take EBITDA, apply a multiple drawn from comparable transactions, then adjust for size and risk. Ordinarily it works, because reported earnings roughly track economic reality.
In cannabis they do not. Section 280E denies ordinary business deductions to any trade or business trafficking in a Schedule I substance, which still covers adult-use activity. So an operator pays federal tax on a base far larger than its actual profit, and reported net income sits well below the economics a buyer is actually acquiring.
Anyone applying a conventional multiple to that figure produces a number with no meaning. Consequently the first step in cannabis business valuation is not choosing a multiple. It is rebuilding the earnings the multiple should apply to.
What Normalising Actually Involves
Separate tax treatment from operations. Model what the business earns before 280E, then model the tax burden as its own line. Otherwise you cannot tell an inefficient operator from a heavily taxed one.
Test the COGS allocation. Cost of goods sold is the only deduction 280E permits, so operators push everything defensible into it. A buyer will test whether that allocation survives examination, because an aggressive one carries exposure that transfers.
Split medical from adult-use. Since April 2026 those two carry different federal tax treatments. Accordingly a dual-licence operator holds two economically different businesses under one roof, and blending them hides which one is actually worth buying. Our guide to 280E expense allocation covers that split in detail.
💬 The Conversation Worth Having
Rescheduling created a gap nobody has closed. A medical operator’s real economics improved permanently in April 2026, yet its trailing financials still show the old tax burden. So a buyer valuing off trailing numbers undervalues the business, while a seller valuing off forward numbers overvalues it. Both sides are looking at defensible figures and reaching incompatible conclusions. Bridging that gap is currently the single most contested question in cannabis business valuation, and it is an accounting question rather than a negotiating one.
Do your financials describe the business as it is today, or as it was taxed last year?
The Three Valuation Approaches, and Which One Survives
Valuation practice recognises three approaches. In cannabis business valuation they do not perform equally, and knowing why matters more than knowing the names.
▶ How Each Approach Holds Up in Cannabis
| Approach | How It Works | In Cannabis |
|---|---|---|
| Income | Discounted cash flow, projecting forward and discounting to present value | Strongest, because it can model 280E and rescheduling explicitly rather than inheriting them |
| Market | Multiples drawn from comparable company or transaction data | Weakest, since private deals go undisclosed and public multiples reflect capital access rather than operations |
| Asset | Net asset value, including identifiable intangibles | Useful as a floor, especially where licence and real estate carry most of the value |
Most credible cannabis valuations weight income heavily, use asset as a floor, and treat market data as a sanity check rather than a conclusion.
Why Public MSO Multiples Mislead
Anyone can pull a multiple from a public multi-state operator. In cannabis business valuation, very few should. Public MSO valuations move on capital access, uplisting expectations, and index inclusion, none of which apply to a private single-state operator. Meanwhile a private operator carries key-person risk and illiquidity that a public company does not.
Therefore treat public multiples as market colour rather than evidence. If your valuation rests on them, expect a buyer’s advisor to say so.
The Licence Is a Separate Asset From the Business
This is where two operators with identical revenue and identical margins reach completely different cannabis business valuation outcomes. It surprises people every time.
In a limited-licence state, where the regulator caps how many licences exist, the licence itself carries scarcity value. A buyer may be paying primarily for entry to a closed market, and the operating business is almost secondary.
In an unlimited-licence state, where anyone meeting the criteria can apply, that scarcity premium disappears. The licence is a compliance requirement rather than an asset, and the valuation rests almost entirely on operations.
Transferability Is the Question Behind the Question
A licence with scarcity value is worth nothing to a buyer who cannot receive it. Most states require regulator approval for a change of ownership or control, and the process takes months rather than weeks. Some restrict transfer entirely, and others impose residency or ownership conditions that disqualify particular buyers.
Consequently transferability belongs in the valuation, not in the closing checklist. A deal structured to avoid a licence transfer is a different deal, at a different price.
What Actually Drives a Cannabis Business Valuation
Beyond the licence, six factors move a cannabis business valuation most. None is exotic, and each is improvable in the twelve to eighteen months before a sale.
1. Whether the records reconcile. Seed-to-sale, point of sale and the general ledger should agree. When they do not, a buyer stops arguing about the multiple and starts discounting for uncertainty instead.
2. The defensibility of the 280E position. An aggressive COGS allocation with no methodology memo behind it is exposure a buyer prices in. Our guide to 280E audit defence covers what that file should contain.
3. Audited or reviewed financials. Unaudited statements invite a discount for uncertainty. That discount is frequently larger than the cost of the audit that would have prevented it.
4. Owner dependence. If relationships with regulators, landlords and vendors live with the founder personally, the buyer is acquiring a book that may not transfer.
5. Real estate and lease terms. Where the owner also holds the property and leases it to the business at a non-market rate, reported earnings are not what a buyer would inherit.
6. Revenue durability. Wholesale revenue concentrated in a handful of retail accounts is fragile. Retail revenue with a repeat customer base is not.
How GreenGrowth CPAs Approaches Cannabis Business Valuation
We have worked with cannabis operators since 2016 and hold PCAOB registration alongside AICPA membership. That combination matters here, because the hard part of a cannabis business valuation is accounting rather than deal mechanics.
A broker can run a multiple. What a broker cannot do is tell you whether the COGS allocation behind your earnings survives examination, whether your inventory ties to seed-to-sale, or what an uncertain tax position does to the purchase price. Those are the questions diligence actually turns on.
What a Valuation Readiness Review Covers
Three things. First, whether your records reconcile well enough to support any cannabis business valuation at all. Second, where your 280E position sits and what a buyer would price for it. Third, which of the six value drivers above is currently costing you most, and what work it would take to fix.
Worth saying plainly: most operators who run this review find the gap is bookkeeping and tax position rather than price expectation. Consequently the answer is rarely a valuation report. More often it is reconciling the records, documenting the 280E methodology, and getting the financials to a standard a buyer will accept. You can see the wider practice on our cannabis accounting page.
KEY TAKEAWAYS
- ›Section 280E suppresses reported earnings, so normalising them comes before any multiple. Applying a conventional multiple to reported net income values a distortion.
- ›Rescheduling created a gap between trailing and forward economics for medical operators. Buyers valuing off trailing numbers and sellers valuing off forward ones both hold defensible figures.
- ›The income approach works best because it can model 280E explicitly. Market comparables are weakest, since private deals go undisclosed and public MSO multiples reflect capital access.
- ›Licence value depends on whether the state caps licences. Transferability belongs in the valuation rather than the closing checklist, since a licence a buyer cannot receive is worth nothing to them.
- ›Six drivers move the number most: record reconciliation, 280E defensibility, audited financials, owner dependence, real estate and lease terms, and revenue durability.
- ›The buyer inherits your open tax positions. An aggressive prior-year allocation or a pending refund claim transfers, and diligence prices it in.
Cannabis Valuation Questions Answered
The Basics
What is cannabis business valuation?+
Cannabis business valuation estimates what a licensed operator is worth, whether for a sale, an investment, a partner exit, or a tax or litigation purpose. It differs from ordinary business valuation because Section 280E suppresses reported earnings, market comparables are scarce, licence value varies enormously by state, and the buyer inherits the seller’s open tax positions.
Why can’t I just apply an EBITDA multiple?+
Because reported earnings do not track economic reality in cannabis. Section 280E denies ordinary deductions for adult-use activity, so an operator pays federal tax on a base far larger than its actual profit. Applying a conventional multiple to that suppressed figure produces a number with no meaning. Normalising the earnings has to come first.
Which valuation approach works best for cannabis?+
The income approach, usually a discounted cash flow, because it can model Section 280E and the rescheduling transition explicitly rather than inheriting them through a multiple. An asset approach works as a floor where licence and real estate carry most of the value. Market comparables are weakest, since private transactions go undisclosed and public multiples reflect capital access rather than operations.
Licences and Rescheduling
How much is a cannabis licence worth?+
It depends almost entirely on whether the state caps how many licences exist. In a limited-licence state the licence carries scarcity value, so a buyer may be paying primarily for market entry. Where the state issues licences without a cap, that premium disappears and the licence becomes a compliance requirement rather than an asset. Transferability matters too, since a licence a buyer cannot receive is worth nothing to them.
How did the April 2026 rescheduling order change valuations?+
It re-rated medical operators permanently, because state-licensed medical cannabis moved to Schedule III and left Section 280E. Trailing financials still show the old tax burden, however, so they describe a business that no longer exists. A buyer valuing off trailing numbers undervalues it, while a seller valuing off forward numbers overvalues it. Bridging that gap is currently the most contested question in cannabis valuation.
Preparing and Next Steps
What lowers a cannabis business valuation most?+
Records that do not reconcile. When seed-to-sale, the point of sale and the general ledger disagree, a buyer stops negotiating the multiple and starts discounting for uncertainty across the whole business. After that, the biggest detractors are an undocumented 280E position, unaudited financials, heavy owner dependence, a non-market related party lease, and revenue concentrated in a few wholesale accounts.
Does the buyer inherit my tax exposure?+
In an equity purchase, generally yes. An aggressive prior-year cost of goods sold allocation, an amended 280E refund claim, or an unresolved examination all transfer with the entity. Diligence prices that in, either as a purchase price reduction or an escrow holdback. Sellers who quantify the exposure before diligence usually keep more of it than sellers who wait to be asked.
Working With GreenGrowth CPAs
How does GreenGrowth CPAs help with cannabis valuation?+
We normalise the earnings a valuation rests on, test whether the records reconcile, and establish where the 280E position sits and what a buyer would price for it. GreenGrowth CPAs has worked with cannabis operators since 2016 and holds PCAOB registration alongside AICPA membership, which matters because the hard part of a cannabis valuation is accounting rather than deal mechanics.
A Multiple Applied to the Wrong Number Is Just a Guess.
Book a valuation readiness review. We normalise the earnings, test the records, and tell you where the exposure sits and what it would take to fix, before a buyer finds it.
GreenGrowth CPAs · Cannabis Advisory Team
